Abstract
Mannan-binding lectin (MBL) is a soluble innate immune protein that binds to glycosylated targets. MBL acts as an opsonin and activates complement, contributing to the destruction and clearance of infecting microorganisms. Hepatitis C virus (HCV) encodes two envelope glycoproteins E1 and E2, expressed as non-covalent E1/E2 heterodimers in the viral envelope. E1 and E2 are potential ligands for MBL. Here we describe an analysis of the interaction between HCV and MBL using recombinant soluble E2 ectodomain fragment, the full-length E1/E2 heterodimer, expressed in vitro, and assess the effect of this interaction on virus entry. A binding assay using antibody capture of full length E1/E2 heterodimers was used to demonstrate calcium dependent, saturating binding of MBL to HCV glycoproteins. Competition with various saccharides further confirmed that the interaction was via the lectin domain of MBL. MBL binds to E1/E2 representing a broad range of virus genotypes. MBL was shown to neutralize the entry into Huh-7 cells of HCV pseudoparticles (HCVpp) bearing E1/E2 from a wide range of genotypes. HCVpp were neutralized to varying degrees. MBL was also shown to neutralize an authentic cell culture infectious virus, strain JFH-1 (HCVcc). Furthermore, binding of MBL to E1/E2 was able to activate the complement system via MBL-associated serine protease 2. In conclusion, MBL interacts directly with HCV glycoproteins, which are present on the surface of the virion, resulting in neutralization of HCV particles.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aasa-Chapman, M.M., Holuigue, S., Aubin, K., Wong, M., Jones, N. A., Cornforth, D., Pellegrino, P., Newton, P., Williams, I., Borrow, P., et al. (2005). Detection of antibody-dependent complementmediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 79, 2823–2830.
Alves Pedroso, M.L., Boldt, A.B., Pereira-Ferrari, L., Steffensen, R., Strauss, E., Jensenius, J.C., Ioshii, S.O., and Messias-Reason, I. (2008). Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy. Clin Exp Immunol 152, 258–264.
Anders, E.M., Hartley, C.A., and Jackson, D.C. (1990). Bovine and mouse serum beta inhibitors of influenza A viruses are mannosebinding lectins. Proc Natl Acad Sci U S A 87, 4485–4489.
Anon. (1999). Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6, 35–47.
Arnold, J.N., Radcliffe, C.M., Wormald, M.R., Royle, L., Harvey, D.J., Crispin, M., Dwek, R.A., Sim, R.B., and Rudd, P.M. (2004). The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannanbinding lectin. J Immunol 173, 6831–6840.
Bartosch, B., Dubuisson, J., and Cosset, F.L. (2003). Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197, 633–642.
Bouwman, L.H., Roos, A., Terpstra, O.T., de Knijff, P., van Hoek, B., Verspaget, H.W., Berger, S.P., Daha, M.R., Frölich, M., van der Slik, A.R., et al. (2005). Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 129, 408–414.
Brown, K.S., Keogh, M.J., Tagiuri, N., Grainge, M.J., Presanis, J.S., Ryder, S.D., Irving, W.L., Ball, J.K., Sim, R.B., and Hickling, T.P. (2007a). Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. Clin Exp Immunol 147, 90–98.
Brown, K.S., Ryder, S.D., Irving, W.L., Sim, R.B., and Hickling, T.P. (2007b). Mannan binding lectin and viral hepatitis. Immunol Lett 108, 34–44.
Chong, W.P., To, Y.F., Ip, W.K., Yuen, M.F., Poon, T.P., Wong, W.H., Lai, C.L., and Lau, Y.L. (2005). Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 42, 1037–1045.
Clayton, R.F., Owsianka, A., Aitken, J., Graham, S., Bhella, D., and Patel, A.H. (2002). Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 76, 7672–7682.
Dumestre-Perard, C., Ponard, D., Drouet, C., Leroy, V., Zarski, J.P., Dutertre, N., and Colomb, M.G. (2002). Complement C4 monitoring in the follow-up of chronic hepatitis C treatment. Clin Exp Immunol 127, 131–136.
Endo, M., Ohsawa, I., Ohi, H., Fujita, T., Matsushita, M., and Fujita, T. (2001). Mannose-binding lectin contributes to glomerulonephritis induced by hepatitis C virus infection. Nephron 87, 374–375.
Farci, P., Alter, H.J., Wong, D.C., Miller, R.H., Govindarajan, S., Engle, R., Shapiro, M., and Purcell, R.H. (1994). Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91, 7792–7796.
Gerlach, J.T., Diepolder, H.M., Jung, M.C., Gruener, N.H., Schraut, W. W., Zachoval, R., Hoffmann, R., Schirren, C.A., Santantonio, T., and Pape, G.R. (1999). Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117, 933–941.
Goffard, A., and Dubuisson, J. (2003). Glycosylation of hepatitis C virus envelope proteins. Biochimie 85, 295–301.
Golden-Mason, L., Madrigal-Estebas, L., McGrath, E., Conroy, M.J., Ryan, E.J., Hegarty, J.E., O’Farrelly, C., and Doherty, D.G. (2008). Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57, 1121–1128.
Hart, M.L., Saifuddin, M., and Spear, G.T. (2003). Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. J Gen Virol 84, 353–360.
Helle, F., Goffard, A., Morel, V., Duverlie, G., McKeating, J., Keck, Z. Y., Foung, S., Penin, F., Dubuisson, J., and Voisset, C. (2007). The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 81, 8101–8111.
Helle, F., Wychowski, C., Vu-Dac, N., Gustafson, K.R., Voisset, C., and Dubuisson, J. (2006). Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 281, 25177–25183.
Iacob, R.E., Perdivara, I., Przybylski, M., and Tomer, K.B. (2008). Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J Am Soc Mass Spectrom 19, 428–444.
Ishii, K., Rosa, D., Watanabe, Y., Katayama, T., Harada, H., Wyatt, C., Kiyosawa, K., Aizaki, H., Matsuura, Y., Houghton, M., et al. (1998). High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28, 1117–1120.
Ji, X., Gewurz, H., and Spear, G.T. (2005a). Mannose binding lectin (MBL) and HIV. Mol Immunol 42, 145–152.
Ji, X., Olinger, G.G., Aris, S., Chen, Y., Gewurz, H., and Spear, G.T. (2005b). Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 86, 2535–2542.
Kilpatrick, D.C., Delahooke, T.E., Koch, C., Turner, M.L., and Hayes, P.C. (2003). Mannan-binding lectin and hepatitis C infection. Clin Exp Immunol 132, 92–95.
Kim, W.R. (2002). The burden of hepatitis C in the United States. Hepatology 36, S30–S34.
Koutsounaki, E., Goulielmos, G.N., Koulentaki, M., Choulaki, C., Kouroumalis, E., and Galanakis, E. (2008). Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virusinfected patients. J Clin Immunol 28, 495–500.
Krarup, A., Wallis, R., Presanis, J.S., Gál, P., Sim, R.B., and Sommer, P. (2007). Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2, e623.
Lavillette, D., Tarr, A.W., Voisset, C., Donot, P., Bartosch, B., Bain, C., Patel, A.H., Dubuisson, J., Ball, J.K., and Cosset, F.L. (2005). Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41, 265–274.
Liu, J., Ali, M.A., Shi, Y., Zhao, Y., Luo, F., Yu, J., Xiang, T., Tang, J., Li, D., Hu, Q., et al. (2009). Specifically binding of L-ficolin to Nglycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol 6, 235–244.
Malhotra, R., Haurum, J.S., Thiel, S., and Sim, R.B. (1994). Binding of human collectins (SP-A and MBP) to influenza virus. Biochem J 304, 455–461.
Matsushita, M., Hijikata, M., Matsushita, M., Ohta, Y., and Mishiro, S. (1998b). Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol 29, 695–700.
Matsushita, M., Hijikata, M., Ohta, Y., Iwata, K., Matsumoto, M., Nakao, K., Kanai, K., Yoshida, N., Baba, K., and Mishiro, S. (1998a). Hepatitis C virus infection and mutations of mannosebinding lectin gene MBL. Arch Virol 143, 645–651.
Mayilyan, K.R., Presanis, J.S., Arnold, J.N., Hajela, K., and Sim, R.B. (2006). Heterogeneity of MBL-MASP complexes. Mol Immunol 43, 1286–1292.
Meyer, K., Basu, A., Przysiecki, C.T., Lagging, L.M., Di Bisceglie, A. M., Conley, A.J., and Ray, R. (2002). Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 76, 2150–2158.
Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T., and Sato, J. (1982). Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42, 3858–3863.
Owsianka, A., Clayton, R.F., Loomis-Price, L.D., McKeating, J.A., and Patel, A.H. (2001). Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82, 1877–1883.
Owsianka, A., Tarr, A.W., Juttla, V.S., Lavillette, D., Bartosch, B., Cosset, F.L., Ball, J.K., and Patel, A.H. (2005). Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79, 11095–11104.
Owsianka, A.M., Tarr, A.W., Keck, Z.Y., Li, T.K., Witteveldt, J., Adair, R., Foung, S.K., Ball, J.K., and Patel, A.H. (2008). Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 89, 653–659.
Pawlotsky, J.M. (2006). Therapy of hepatitis C: from empiricism to eradication. Hepatology 43, S207–S220.
Pestka, J.M., Zeisel, M.B., Bläser, E., Schürmann, P., Bartosch, B., Cosset, F.L., Patel, A.H., Meisel, H., Baumert, J., Viazov, S., et al. (2007). Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104, 6025–6030.
Pulendran, B., and Ahmed, R. (2006). Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849–863.
Reading, P.C., Morey, L.S., Crouch, E.C., and Anders, E.M. (1997). Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J Virol 71, 8204–8212.
Sanders, C.J., Yu, Y., Moore, D.A. 3rd, Williams, I.R., and Gewirtz, A. T. (2006). Humoral immune response to flagellin requires T cells and activation of innate immunity. J Immunol 177, 2810–2818.
Sasaki, K., Tsutsumi, A., Wakamiya, N., Ohtani, K., Suzuki, Y., Watanabe, Y., Nakayama, N., and Koike, T., and K. Sasaki, A. Tsutsumi, N. Wakamiya. (2000). Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterol 35, 960–965.
Simmonds, P., Bukh, J., Combet, C., Deléage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspé, G., Kuiken, C., Maertens, G., et al. (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962–973.
Steinmann, D., Barth, H., Gissler, B., Schürmann, P., Adah, M.I., Gerlach, J.T., Pape, G.R., Depla, E., Jacobs, D., Maertens, G., et al. (2004). Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol 78, 9030–9040.
Takehara, T., and Hayashi, N. (2005). Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity. Clin Gastroenterol Hepatol 3, S78–S81.
Tan, S.M., Chung, M.C., Kon, O.L., Thiel, S., Lee, S.H., and Lu, J. (1996). Improvements on the purification of mannan-binding lectin and demonstration of its Ca(2 +)-independent association with a C1s-like serine protease. Biochem J 319, 329–332.
Tarr, A.W., Owsianka, A.M., Timms, J.M., McClure, C.P., Brown, R.J., Hickling, T.P., Pietschmann, T., Bartenschlager, R., Patel, A.H., and Ball, J.K. (2006). Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43, 592–601.
Thiel, S., Holmskov, U., Hviid, L., Laursen, S.B., and Jensenius, J.C. (1992). The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol 90, 31–35.
Thiel, S., Vorup-Jensen, T., Stover, C.M., Schwaeble, W., Laursen, S. B., Poulsen, K., Willis, A.C., Eggleton, P., Hansen, S., Holmskov, U., et al. (1997). A second serine protease associated with mannan-binding lectin that activates complement. Nature 386, 506–510.
Thimme, R., Oldach, D., Chang, K.M., Steiger, C., Ray, S.C., and Chisari, F.V. (2001). Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194, 1395–1406.
Vallinoto, A.C., da Silva, R.F., Hermes, R.B., Amaral, I.S., Miranda, E. C., Barbosa, M.S., Moia, L.J., Conde, S.R., Soares, M.C., Lemos, J.A., et al. (2009). Mannose-binding lectin gene polymorphisms are not associated with susceptibility to hepatitis C virus infection in the Brazilian Amazon region. Hum Immunol 70, 754–757.
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.G., Mizokami, M., et al. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11, 791–796.
Weis, W.I., Drickamer, K., and Hendrickson, W.A. (1992). Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 360, 127–134.
Yamada, E., Montoya, M., Schuettler, C.G., Hickling, T.P., Tarr, A.W., Vitelli, A., Dubuisson, J., Patel, A.H., Ball, J.K., and Borrow, P. (2005). Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J Gen Virol 86, 2507–2512.
Yanagi, M., Purcell, R.H., Emerson, S.U., and Bukh, J. (1997). Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A 94, 8738–8743.
Ying, H., Ji, X., Hart, M.L., Gupta, K., Saifuddin, M., Zariffard, M.R., and Spear, G.T. (2004). Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses 20, 327–335.
Zhang, M., Rosenberg, P.S., Brown, D.L., Preiss, L., Konkle, B.A., Eyster, M.E., and Goedert, J.J., and the Second Multicenter Hemophilia Cohort Study. (2006). Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 107, 892–897.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brown, K.S., Keogh, M.J., Owsianka, A.M. et al. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 1, 664–674 (2010). https://doi.org/10.1007/s13238-010-0088-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13238-010-0088-9